Katherine Hand is an associate in the firm’s Business Law department and a member of its Technology and Life Sciences groups and Shareholder Activism & Takeover Defense practice. She represents public and private companies in the life sciences and technology industries throughout the full range of the corporate life cycle, including startup and formation matters, venture capital financings, initial public offerings and capital markets transactions, and other complex transactions. Katherine also advises companies on ongoing SEC compliance and corporate governance matters and shareholder activism matters. She joined Goodwin in 2018.
Representative Matters
- Alkermes plc in the spin-off of its oncology business into Mural Oncology plc
- Bluebird bio, Inc. in the spin-off of its oncology programs and portfolio into 2seventy bio, Inc.
- 2seventy bio, Inc. in its $170 million PIPE financing and its $125 million public offering
- Akero Therapeutics, Inc. in its initial public offering, multiple follow-on offerings of more than $425 million, a $25 million equity investment by Pfizer, Inc., its $100 million term loan facility with Hercules Capital, Inc. and day-to-day governance and reporting matters
- Tango Therapeutics, Inc. in connection with its $60 million Series B financing, its $1.0 billion definitive business combination with BCTG Acquisition Corp and its $80 million PIPE financing
- Clarus Therapeutics in connection with its definitive business combination
- Avadel Pharmaceuticals plc in its $65 million financing transaction, $125 million follow-on offering and $125 million follow-on offering
- ElevateBio, LLC in connection with its $193 million Series B financing, $525 million Series C financing, its $401 million Series D financing and the formation of its portfolio companies
- Openly in its $100 million Series D financing and other preferred stock financings
- Imagen Technologies, Inc. in its preferred stock financings
- Firefly Health, Inc. in its preferred stock financings
- Versanis Bio, Inc. in its $113 million Series B financing and other preferred stock financings
- Vizit Labs, Inc. it its preferred stock financings
- Zus Health, Inc. in its $34M Series A financing and other preferred stock financings
- Versanis Bio, Inc. in its merger with Eli Lilly and Company
- Fincura, in its sale to Numerated
- Mavrck, in its combination with Later
Katherine has provided associate support for shareholder activism matters including for Anika Therapeutics, Cedar Realty Trust, Virtusa and Leaf Group in their defenses against activist campaigns.
Areas of Practice
Professional Activities
Katherine is a member of the Boston Bar Association.
Professional Experience
Prior to joining Goodwin, Katherine completed a legal fellowship with TripAdvisor
Credentials
Education
JD2016
Boston College Law School
BSChemistry
Boston College
Admissions
Bars
- Massachusetts
Recognition & Awards
Katherine has been recognized by the Legal 500 US for her work in Shareholder Activism in 2023 and 2024.